ステラーラ（ウステキヌマブ）の世界市場レポート2025年：疫学、パイプライン分析、市場インサイトと予測

ステラーラ（ウステキヌマブ）市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6%で147億6,850万米ドルに成長します。この予測期間における成長は、ステラーラの適応拡大、自己免疫疾患の有病率の増加、代替薬と比較した難治性症例における高い有効性、患者やヘルスケアプロバイダの意識の高まり、個別化医療への注目の高まりなどに起因すると考えられます。予測期間における主要動向としては、生物製剤の採用、先進ドラッグデリバリーシステムの開発、データ駆動型ヘルスケアシステム、製薬企業間の提携やライセンシング契約、生物製剤の製造技術の進歩などが挙げられます。

乾癬の有病率の増加は、今後のステラーラ（ウステキヌマブ）市場の成長を牽引すると予想されます。乾癬患者は、皮膚細胞のターンオーバーを早める慢性的な自己免疫疾患であり、その結果、赤くうろこ状の斑点が生じます。乾癬の有病率の増加は、診断の向上、環境的誘因、遺伝的素因、高齢化などの要因によるものです。ステラーラ（ウステキヌマブ）はインターロイキン-12とインターロイキン-23を標的として阻害することにより作用し、炎症とプラーク形成を効果的に抑えることにより乾癬患者を助けます。これにより、皮膚のクリアランスが改善し、長期的な症状管理が可能となり、最終的に患者のQOLが向上します。例えば、2024年5月、米国を拠点とする医療図書館National Library of Medicineの報告によると、2022年、乾癬の有病率は0.221％に増加し、人口313万3,500人において6,930例のPsAが報告されました。その結果、乾癬患者の有病率の上昇がステラーラ（ウステキヌマブ）市場の成長を促進すると予想されます。

ステラーラ（ウステキヌマブ）市場の主要動向は、慢性炎症性疾患患者に費用対効果の高い治療選択肢を提供するStelaraバイオシミラーなどの革新的製品の開拓です。ステラーラバイオシミラーは生物学的に類似した医薬品で、ステラーラ（ウステキヌマブ）の治療効果を再現するように設計されており、IL-12とIL-23を標的とし、乾癬や乾癬性関節炎のような自己免疫疾患を治療します。例えば、2024年10月、米国を拠点とするバイオ医薬品会社Accord BioPharma Inc.は、ジョンソン・エンド・ジョンソンのステラーラ（ウステキヌマブ）のバイオシミラーであるIMULDOSA（ustekinumab-srlf）を米国食品医薬品局（FDA）が承認したと発表しました。IMULDOSAは、中等症から重症の尋常性乾癬、活動性関節症性乾癬、中等症から重症の活動性クローン病、潰瘍性大腸炎の成人患者を治療対象とする、幅広い適応症で注目されています。また、中等度から重度の尋常性乾癬と活動性関節症性乾癬を有する6歳以上の小児患者にも独自の適応を有しており、様々な年齢層に汎用されています。このような幅広い適応症により、イムルドーザは様々な免疫介在性炎症性疾患に対する貴重な治療として位置づけられています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 バイオ医薬品市場における製品特性

• 分子タイプ
• 投与経路（ROA）
• 作用機序（MOA）
• 安全性と有効性

第4章 市場動向と戦略

第5章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症、景気回復が市場に与える影響を含むマクロ経済シナリオ

第6章 世界の成長分析と戦略分析フレームワーク

• 世界のステラーラ（ウステキヌマブ）：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のステラーラ（ウステキヌマブ）市場：成長率分析
• 世界のステラーラ（ウステキヌマブ）市場の実績：規模と成長、2019～2024年
• 世界のステラーラ（ウステキヌマブ）市場の予測：規模と成長、2024～2029年、2034年
• 世界のステラーラ（ウステキヌマブ）：総潜在市場規模（TAM）

第7章 世界市場の価格分析と予測

第8章 市場セグメンテーション

• 世界のステラーラ（ウステキヌマブ）市場：適応症別、実績と予測、2019～2024年、2024～2029年、2034年
• 尋常性乾癬
• 乾癬性関節炎
• クローン病
• 潰瘍性大腸炎
• その他
• 世界のステラーラ（ウステキヌマブ）市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 皮下注射
• 静脈内注入
• 世界のステラーラ（ウステキヌマブ）市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のステラーラ（ウステキヌマブ）市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 小児
• 成人
• 高齢者

第9章 臨床適応症の世界市場疫学

• 薬剤の副作用
• 臨床適応症の発症率と有病率

第10章 地域別・国別分析

• 世界のステラーラ（ウステキヌマブ）市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のステラーラ（ウステキヌマブ）市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第11章 アジア太平洋市場

第12章 中国市場

第13章 インド市場

第14章 日本市場

第15章 オーストラリア市場

第16章 韓国市場

第17章 西欧市場

第18章 英国市場

第19章 ドイツ市場

第20章 フランス市場

第21章 東欧市場

第22章 北米市場

第23章 米国市場

第24章 カナダ市場

第25章 南米市場

第26章 中東市場

第27章 アフリカ市場

第28章 競合情勢と企業プロファイル

• ステラーラ（ウステキヌマブ）市場：競合情勢
• ステラーラ（ウステキヌマブ）市場：企業プロファイル
  • Johnson & Johnson

第29章 世界市場：パイプライン分析

第30章 世界の市場競合ベンチマーキングとダッシュボード

第31章 主要な合併と買収

第32章 最近の市場動向

第33章 市場の潜在力が高い国、戦略

• ステラーラ（ウステキヌマブ）市場、2029年：新たな機会を提供する国
• ステラーラ（ウステキヌマブ）市場、2029年：新たな機会を提供するセグメント
• ステラーラ（ウステキヌマブ）市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第34章 付録

Stelara (Ustekinumab) is a monoclonal antibody that targets interleukin-12 (IL-12) and interleukin-23 (IL-23), two key proteins involved in inflammatory and autoimmune responses. It is commonly used to treat conditions such as moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary indications for stelara (Ustekinumab) include plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and other conditions. Plaque psoriasis is a chronic autoimmune disorder that leads to the rapid buildup of skin cells, creating scaly, inflamed patches, often on the scalp, elbows, and knees. Stelara can be administered via subcutaneous injection or intravenous infusion and is available through various distribution channels, including hospital, retail, and online pharmacies. It is used for pediatric, adult, and geriatric patients.

The stelara (ustekinumab) market research report is one of a series of new reports from The Business Research Company that provides stelara (ustekinumab) market statistics, including stelara (ustekinumab) industry global market size, regional shares, competitors with a stelara (ustekinumab) market share, detailed stelara (ustekinumab) market segments, market trends and opportunities, and any further data you may need to thrive in the stelara (ustekinumab) industry. This stelara (ustekinumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The stelara (ustekinumab) market size is expected to see strong growth in the next few years. It will grow to $14,768.5 million in 2029 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to expanding indications for stelara, increasing prevalence of autoimmune diseases, high efficacy in refractory cases compared to alternatives, rising awareness among patients and healthcare providers, growing focus on personalized medicine. Major trends in the forecast period include adoption of biologic therapies, development of advanced drug delivery systems, data-driven healthcare systems, partnerships and licensing agreements between pharmaceutical companies, advances in biologics manufacturing technologies.

The growing prevalence of psoriasis is expected to drive the growth of the stelara (ustekinumab) market in the future. Psoriasis patients are individuals dealing with a chronic autoimmune disorder that speeds up skin cell turnover, resulting in red, scaly patches. The rise in psoriasis prevalence can be attributed to factors such as better diagnosis, environmental triggers, genetic predisposition, and an aging population. Stelara (ustekinumab) works by targeting and inhibiting interleukin-12 and interleukin-23, which helps psoriasis patients by effectively reducing inflammation and plaque formation. This leads to improved skin clearance and long-term symptom management, ultimately enhancing patients' quality of life. For instance, in May 2024, a report from the National Library of Medicine, a U.S.-based medical library, revealed that in 2022, psoriasis prevalence increased to 0.221%, with 6,930 cases of PsA reported in a population of 3,133,500. As a result, the rising prevalence of psoriasis patients is expected to fuel the growth of the stelara (ustekinumab) market.

A key trend in the stelara (ustekinumab) market is the development of innovative products, such as Stelara biosimilars, which offer a cost-effective treatment option for patients with chronic inflammatory conditions. Stelara biosimilars are biologically similar medications designed to replicate the therapeutic effects of Stelara (Ustekinumab), targeting IL-12 and IL-23 to treat autoimmune diseases like psoriasis and psoriatic arthritis. For example, in October 2024, Accord BioPharma Inc., a U.S.-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved IMULDOSA (ustekinumab-srlf), a biosimilar to Johnson & Johnson's STELARA (ustekinumab). IMULDOSA is notable for its broad indications, providing treatment for adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn's disease, and ulcerative colitis. It is also uniquely indicated for pediatric patients aged 6 years and older with moderate to severe plaque psoriasis and active psoriatic arthritis, making it versatile across different age groups. This wide range of indications positions IMULDOSA as a valuable treatment for various immune-mediated inflammatory diseases.

In December 2023, Lotus Pharmaceutical, a Taiwan-based pharmaceutical company, partnered with Favorex Pte Ltd. to introduce a biosimilar of ustekinumab to the South Korean market. With this collaboration, Lotus Pharmaceutical aims to leverage Favorex Pte Ltd.'s expertise and market presence to bring a cost-effective biosimilar of ustekinumab to South Korea, addressing the demand for affordable biologic therapies while expanding its presence in the region's pharmaceutical sector. Favorex Pte Ltd. is a pharmaceutical company based in Singapore.

The Key player operating in the stelara (ustekinumab) market is Johnson & Johnson.

North America was the largest region in the stelara (ustekinumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in stelara (ustekinumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the stelara (ustekinumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The stelara (ustekinumab) market consists of sales of small-molecule drugs, vaccines, immunotherapy products, biosimilars and injectable drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Stelara (Ustekinumab) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on stelara (ustekinumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for stelara (ustekinumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The stelara (ustekinumab) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Indication: Plaque Psoriasis; Psoriatic Arthritis; Crohn's Disease; Ulcerative Colitis; Other Indications
• 2) By Route Of Administration: Subcutaneous Injection; Intravenous Infusion
• 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• 4) By End User: Pediatric; Adult; Geriatric
• Companies Mentioned: Johnson & Johnson
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Stelara (Ustekinumab) Market Characteristics

3. Stelara (Ustekinumab) Market Biologic Drug Characteristics

• 3.1. Molecule Type
• 3.2. Route Of Administration (ROA)
• 3.3. Mechanism Of Action (MOA)
• 3.4. Safety And Efficacy

4. Stelara (Ustekinumab) Market Trends And Strategies

5. Stelara (Ustekinumab) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Stelara (Ustekinumab) Growth Analysis And Strategic Analysis Framework

• 6.1. Global Stelara (Ustekinumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 6.2. Analysis Of End Use Industries
• 6.3. Global Stelara (Ustekinumab) Market Growth Rate Analysis
• 6.4. Global Stelara (Ustekinumab) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 6.5. Global Stelara (Ustekinumab) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 6.6. Global Stelara (Ustekinumab) Total Addressable Market (TAM)

7. Global Stelara (Ustekinumab) Market Pricing Analysis & Forecasts

8. Stelara (Ustekinumab) Market Segmentation

• 8.1. Global Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Plaque Psoriasis
• Psoriatic Arthritis
• Crohn's Disease
• Ulcerative Colitis
• Other Indications
• 8.2. Global Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Subcutaneous Injection
• Intravenous Infusion
• 8.3. Global Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 8.4. Global Stelara (Ustekinumab) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric
• Adult
• Geriatric

9. Global Stelara (Ustekinumab) Market Epidemiology Of Clinical Indications

• 9.1. Drug Side Effects
• 9.2. Incidence And Prevalence of Clinical Indications

10. Stelara (Ustekinumab) Market Regional And Country Analysis

• 10.1. Global Stelara (Ustekinumab) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. Global Stelara (Ustekinumab) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Asia-Pacific Stelara (Ustekinumab) Market

• 11.1. Asia-Pacific Stelara (Ustekinumab) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Asia-Pacific Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Asia-Pacific Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. China Stelara (Ustekinumab) Market

• 12.1. China Stelara (Ustekinumab) Market Overview
• 12.2. China Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.3. China Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.4. China Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

13. India Stelara (Ustekinumab) Market

• 13.1. India Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. India Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. India Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. Japan Stelara (Ustekinumab) Market

• 14.1. Japan Stelara (Ustekinumab) Market Overview
• 14.2. Japan Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. Japan Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. Japan Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Australia Stelara (Ustekinumab) Market

• 15.1. Australia Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.2. Australia Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Australia Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. South Korea Stelara (Ustekinumab) Market

• 16.1. South Korea Stelara (Ustekinumab) Market Overview
• 16.2. South Korea Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. South Korea Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.4. South Korea Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Western Europe Stelara (Ustekinumab) Market

• 17.1. Western Europe Stelara (Ustekinumab) Market Overview
• 17.2. Western Europe Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Western Europe Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.4. Western Europe Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. UK Stelara (Ustekinumab) Market

• 18.1. UK Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. UK Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. UK Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Germany Stelara (Ustekinumab) Market

• 19.1. Germany Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Germany Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Germany Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. France Stelara (Ustekinumab) Market

• 20.1. France Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. France Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. France Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Stelara (Ustekinumab) Market

• 21.1. Eastern Europe Stelara (Ustekinumab) Market Overview
• 21.2. Eastern Europe Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. North America Stelara (Ustekinumab) Market

• 22.1. North America Stelara (Ustekinumab) Market Overview
• 22.2. North America Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. North America Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.4. North America Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. USA Stelara (Ustekinumab) Market

• 23.1. USA Stelara (Ustekinumab) Market Overview
• 23.2. USA Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. USA Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. USA Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. Canada Stelara (Ustekinumab) Market

• 24.1. Canada Stelara (Ustekinumab) Market Overview
• 24.2. Canada Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. Canada Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. Canada Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. South America Stelara (Ustekinumab) Market

• 25.1. South America Stelara (Ustekinumab) Market Overview
• 25.2. South America Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. South America Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. South America Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. Middle East Stelara (Ustekinumab) Market

• 26.1. Middle East Stelara (Ustekinumab) Market Overview
• 26.2. Middle East Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. Middle East Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. Middle East Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Africa Stelara (Ustekinumab) Market

• 27.1. Africa Stelara (Ustekinumab) Market Overview
• 27.2. Africa Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Africa Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.4. Africa Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Stelara (Ustekinumab) Market Competitive Landscape And Company Profiles

• 28.1. Stelara (Ustekinumab) Market Competitive Landscape
• 28.2. Stelara (Ustekinumab) Market Company Profiles
  • 28.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis

29. Global Stelara (Ustekinumab) Market Pipeline Analysis

• 29.1. High Level Clinic Trail Information

30. Global Stelara (Ustekinumab) Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Stelara (Ustekinumab) Market

32. Recent Developments In The Stelara (Ustekinumab) Market

33. Stelara (Ustekinumab) Market High Potential Countries, Segments and Strategies

• 33.1 Stelara (Ustekinumab) Market In 2029 - Countries Offering Most New Opportunities
• 33.2 Stelara (Ustekinumab) Market In 2029 - Segments Offering Most New Opportunities
• 33.3 Stelara (Ustekinumab) Market In 2029 - Growth Strategies
  • 33.3.1 Market Trend Based Strategies
  • 33.3.2 Competitor Strategies

34. Appendix

• 34.1. Abbreviations
• 34.2. Currencies
• 34.3. Historic And Forecast Inflation Rates
• 34.4. Research Inquiries
• 34.5. The Business Research Company
• 34.6. Copyright And Disclaimer